Some investors asked Betta Pharmaceuticals on an interactive platform. On October 2, 2026, Abbott Biotech and global multinational pharmaceutical giant Novartis announced that they had reached an agreement on licensing and licensing options. Novartis took a strong step to acquire an exclusive global license for ABO2203, Abbott Biotech's first mRNA-coding T-cell connector, and obtained exclusive licensing options to develop several innovative projects based on the AbbotRNA platform. Does Betta Pharmaceuticals and Ecosystem companies have a layout, and will they join pipeline project development in the future? Betta Pharmaceuticals replied that the company currently has no relevant layout in the mRNA field. The company will continue to monitor developments in cutting-edge technology, carefully evaluate relevant cooperation opportunities in line with its own development strategy, and promptly announce any significant developments.

Zhitongcaijing · 2d ago
Some investors asked Betta Pharmaceuticals on an interactive platform. On October 2, 2026, Abbott Biotech and global multinational pharmaceutical giant Novartis announced that they had reached an agreement on licensing and licensing options. Novartis took a strong step to acquire an exclusive global license for ABO2203, Abbott Biotech's first mRNA-coding T-cell connector, and obtained exclusive licensing options to develop several innovative projects based on the AbbotRNA platform. Does Betta Pharmaceuticals and Ecosystem companies have a layout, and will they join pipeline project development in the future? Betta Pharmaceuticals replied that the company currently has no relevant layout in the mRNA field. The company will continue to monitor developments in cutting-edge technology, carefully evaluate relevant cooperation opportunities in line with its own development strategy, and promptly announce any significant developments.